Surface Oncology Analyst Ratings
Surface Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2022 | 365.12% | HC Wainwright & Co. | $8.5 → $6 | Maintains | Buy |
| 08/08/2022 | 558.91% | HC Wainwright & Co. | $10 → $8.5 | Maintains | Buy |
| 05/18/2021 | 1217.83% | BTIG | → $17 | Initiates Coverage On | → Buy |
| 09/04/2020 | 752.71% | HC Wainwright & Co. | → $11 | Initiates Coverage On | → Buy |
| 08/28/2020 | 830.23% | Wedbush | → $12 | Initiates Coverage On | → Outperform |
| 09/19/2018 | 1682.95% | Baird | → $23 | Initiates Coverage On | → Outperform |
| 05/14/2018 | 1217.83% | Goldman Sachs | → $17 | Initiates Coverage On | → Neutral |
| 05/14/2018 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 05/14/2018 | 1915.5% | Evercore ISI Group | → $26 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 11/03/2022 | 365.12% | HC Wainwright & Co. | 8.5 美元 → 6 美元 | 維持 | 購買 |
| 08/08/2022 | 558.91% | HC Wainwright & Co. | 10 美元 → 8.5 美元 | 維持 | 購買 |
| 05/18/2021 | 1217.83% | BTIG | → 17 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 2020 年 4 月 9 日 | 752.71% | HC Wainwright & Co. | → 11 美元 | 啓動覆蓋範圍開啓 | → 購買 |
| 08/28/2020 | 830.23% | Wedbush | → 12 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 09/19/2018 | 1682.95% | 貝爾德 | → 23 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 05/14/2018 | 1217.83% | 高盛 | → 17 美元 | 啓動覆蓋範圍開啓 | → 中立 |
| 05/14/2018 | — | Cowen & Co. | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 05/14/2018 | 1915.5% | Evercore ISI 集團 | → 26 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
Surface Oncology Questions & Answers
表面腫瘤學問題與解答
The latest price target for Surface Oncology (NASDAQ: SURF) was reported by HC Wainwright & Co. on November 3, 2022. The analyst firm set a price target for $6.00 expecting SURF to rise to within 12 months (a possible 365.12% upside). 2 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年11月3日公佈了表面腫瘤學（納斯達克股票代碼：SURF）的最新目標股價。該分析公司將目標股價定爲6.00美元，預計SURF將在12個月內上漲至6.00美元（可能上漲365.12％）。去年有兩家分析公司公佈了評級。
The latest analyst rating for Surface Oncology (NASDAQ: SURF) was provided by HC Wainwright & Co., and Surface Oncology maintained their buy rating.
表面腫瘤學（納斯達克股票代碼：SURF）的最新分析師評級由HC Wainwright & Co. 提供，Surface Oncology維持其買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Surface Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Surface Oncology was filed on November 3, 2022 so you should expect the next rating to be made available sometime around November 3, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Surface Oncology的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。表面腫瘤學的最新評級是在2022年11月3日提交的，因此您應該預計下一個評級將在2023年11月3日左右公佈。
While ratings are subjective and will change, the latest Surface Oncology (SURF) rating was a maintained with a price target of $8.50 to $6.00. The current price Surface Oncology (SURF) is trading at is $1.29, which is out of the analyst's predicted range.
儘管評級是主觀的，並將發生變化，但最新的表面腫瘤學（SURF）評級維持不變，目標股價爲8.50美元至6.00美元。Surface Oncology（SURF）目前的交易價格爲1.29美元，超出了分析師的預測區間。